---
url: https://link.springer.com/article/10.1007/s44345-025-00037-5
title: "AI-enabled drug and molecular discovery: computational methods, platforms, and translational horizons | Discover Molecules"
clipped: 2025-12-29 00:46
source: browser-history
---

# AI-enabled drug and molecular discovery: computational methods, platforms, and translational horizons | Discover Molecules

> Source: [https://link.springer.com/article/10.1007/s44345-025-00037-5](https://link.springer.com/article/10.1007/s44345-025-00037-5)

AI-enabled drug and molecular discovery: computational methods, platforms, and translational horizons

[Download PDF](/content/pdf/10.1007/s44345-025-00037-5.pdf)

## Abstract

The integration of artificial intelligence (AI) with bioinformatics has initiated a transformative shift in drug discovery, redefining how pharmaceutical research and development are conducted. This review examines both the current state and emerging prospects of AI-driven strategies across the drug discovery pipeline, from target identification and molecular design to clinical applications. Advances in machine learning, deep learning, graph neural networks, transformers, foundation models, and quantum computing have shown remarkable potential in overcoming long-standing bottlenecks of conventional drug development, which on average requires 12.5 years and over $2 billion to bring a single drug to market. The AI in pharmaceuticals market, valued at $1.8 billion in 2023, is projected to reach $13.1 billion by 2030, reflecting a compound annual growth rate of 18.8%. Landmark breakthroughs such as AlphaFold, which has generated over 200 million predicted protein structures and more than 20,000 citations, have established new paradigms in structural biology and drug design, while emerging tools like RFdiffusion and AlphaFold3 further extend capabilities into *de novo* protein design and multi-omics integration. AI-enabled workflows have demonstrated the ability to compress discovery timelines from five years to as little as 12–18 months and reduce costs by up to 40%. Despite these advances, significant challenges remain, including issues of data quality and bias, model transparency and interpretability, computational resource demands, and ethical concerns regarding privacy and algorithmic fairness. This review synthesizes findings from recent studies to provide a roadmap for the responsible and reproducible integration of AI into bioinformatics and drug discovery, while outlining critical gaps and future research priorities essential for clinical translation.

### Similar content being viewed by others

![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1186%2Fs40364-025-00758-2/MediaObjects/40364_2025_758_Fig1_HTML.png)

### [Integrating artificial intelligence in drug discovery and early drug development: a transformative approach](https://link.springer.com/10.1186/s40364-025-00758-2?fromPaywallRec=false)

Article
Open access
14 March 2025

![](https://media.springernature.com/w92h120/springer-static/cover-hires/book/978-981-97-2596-0?as=webp)

### [AI-Enabled Models in the Restoration of Drug Efficacy and Drug Design](https://link.springer.com/10.1007/978-981-97-2596-0_5?fromPaywallRec=false)

Chapter
© 2024

![](https://media.springernature.com/w92h120/springer-static/cover-hires/book/978-3-031-93623-4?as=webp)

### [The Future of Drug Discovery: An AI-Driven Perspective](https://link.springer.com/10.1007/978-3-031-93623-4_11?fromPaywallRec=false)

Chapter
© 2025

### Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

* [Pharmaceutics](/subjects/pharmaceutics)
* [Pharmacoeconomics](/subjects/pharmacoeconomics)
* [Phenotypic Drug Screening](/subjects/phenotypic-drug-screening)
* [Structure-Based Drug Design](/subjects/structure-based-drug-design)
* [Virtual Drug Screening](/subjects/virtual-drug-screening)
* [Drug Development](/subjects/drug-development)

[Use our pre-submission checklist](https://beta.springernature.com/pre-submission?journalId=44345)

Avoid common mistakes on your manuscript.

## 1 Introduction

Drug discovery has a long history, originating in ancient civilizations where remedies derived from natural sources were employed for physical and spiritual healing. Modern drug discovery, which emerged in the early twentieth century, typically begins with academic research aimed at identifying disease-related macromolecules, pathways, or mechanisms during the pre-discovery stage. The process involves multiple steps target identification, hit discovery, lead optimization, preclinical evaluation, and clinical trials that demand multidisciplinary expertise and advanced technologies to identify and validate therapeutic candidates [[1](/article/10.1007/s44345-025-00037-5#ref-CR1 "Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239–49."), [2](/article/10.1007/s44345-025-00037-5#ref-CR2 "Singh N, Vayer P, Tanwar S, Poyet JL, Tsaioun K, Villoutreix BO. Drug discovery and development: introduction to the general public and patient groups. Front Drug Discov. 2023;3:1201419.")]. Despite advances in experimental technologies, high attrition rates and escalating development costs continue to pose major challenges.

In recent years, artificial intelligence (AI) has emerged as a transformative force in pharmaceutical research. AI methodologies including machine learning (ML), deep learning (DL), reinforcement learning (RL), and natural language processing (NLP) enable the rapid analysis of vast chemical and biological datasets, prediction of molecular properties, hypothesis generation, and automated molecule design [[3](/article/10.1007/s44345-025-00037-5#ref-CR3 "Adekunle JJ, Lawal MM, Abiodun WO, Nwose CC, Faderin E. (2024). The role of AI and ML in drug discovery and development. J Afr Innov Adv Stud. 5(2), 43–54 "), [4](/article/10.1007/s44345-025-00037-5#ref-CR4 "Albani FG, Alghamdi SS, Almutairi MM, Alqahtani T. Artificial intelligence-driven innovations in oncology drug discovery: transforming traditional pipelines and enhancing drug design. Drug Des Devel Ther. 2025 Jul 3;19:5685–5707. 
                  https://doi.org/10.2147/DDDT.S509769
                  
                .")]. These approaches offer the potential to accelerate multiple stages of the drug discovery pipeline, from virtual screening and structural modeling to toxicity prediction and clinical trial optimization.

A wide range of AI platforms and tools exemplify this transformation. IBM Watson and Benevolent AI assist in data analysis and target identification; DeepMind’s AlphaFold has revolutionized protein structure prediction; Atom wise and Schrödinger employ deep learning and computational chemistry for molecular interaction prediction; OpenAI’s GPT models support hypothesis generation and text mining; while NVIDIA Clara provides infrastructure for genomics and medical imaging [[3](/article/10.1007/s44345-025-00037-5#ref-CR3 "Adekunle JJ, Lawal MM, Abiodun WO, Nwose CC, Faderin E. (2024). The role of AI and ML in drug discovery and development. J Afr Innov Adv Stud. 5(2), 43–54 "), [5](#ref-CR5 "Senior AW, Evans R, Jumper J, Kirkpatrick J, Sifre L, Green T, Hassabis D. Improved protein structure prediction using potentials from deep learning. Nature. 2020;577(7792):706–10."),[6](#ref-CR6 "Wallach I, Dzamba M, Heifets A. (2015). AtomNet: a deep convolutional neural network for bioactivity prediction in structure-based drug discovery. arXiv preprint arXiv:1510.02855."),[7](/article/10.1007/s44345-025-00037-5#ref-CR7 "Brown T, Mann B, Ryder N, Subbiah M, Kaplan JD, Dhariwal P, et al. Language models are few-shot learners. Adv Neural Inf Process Syst. 2020;33:1877–901.")]. Together, these platforms enhance predictive accuracy, streamline experimental workflows, and accelerate the overall pace of drug discovery. Neural networks contribute to predicting molecular bioactivity [[6](/article/10.1007/s44345-025-00037-5#ref-CR6 "Wallach I, Dzamba M, Heifets A. (2015). AtomNet: a deep convolutional neural network for bioactivity prediction in structure-based drug discovery. arXiv preprint arXiv:1510.02855.")], deep learning advances structural biology and biomedical data analysis [[5](/article/10.1007/s44345-025-00037-5#ref-CR5 "Senior AW, Evans R, Jumper J, Kirkpatrick J, Sifre L, Green T, Hassabis D. Improved protein structure prediction using potentials from deep learning. Nature. 2020;577(7792):706–10.")], and reinforcement learning improves molecular design and treatment optimization [[8](/article/10.1007/s44345-025-00037-5#ref-CR8 "Segler MH, Preuss M, Waller MP. Planning chemical syntheses with deep neural networks and symbolic AI. Nature. 2018;555(7698):604–10.")].

The purpose of this paper is to provide a comprehensive narrative overview of how AI-driven methods, computational platforms, and translational applications are reshaping drug and molecule discovery. It is important to clarify that this work is a narrative review, synthesizing key developments and trends from the literature to offer a broad perspective on the field. Unlike a systematic review, it does not follow strict, protocol-driven literature selection criteria. Instead, it surveys core AI methodologies including machine learning, deep learning, reinforcement learning, and natural language processing alongside the databases and tools that enable their deployment, with the aim of illustrating the transformative impact and current landscape of AI in pharmacology.

This overview highlights the application of these technologies across the discovery pipeline, from hit identification and *de novo* molecular design to ADMET prediction, target validation, and drug repurposing. It also explores synergies with complementary innovations such as CRISPR, quantum computing, and high-throughput screening, illustrated through case studies from academia and industry. This paper discusses current challenges, ethical considerations, and future directions, offering a perspective on responsibly integrating AI into next-generation drug discovery to maximize translational impact. The growing economic impact and performance metrics of AI in drug discovery are summarized in Table [1](/article/10.1007/s44345-025-00037-5#Tab1).

**Table 1 Market statistics and performance metrics**

[Full size table](/article/10.1007/s44345-025-00037-5/tables/1)

## 2 Evolution of computational biology

The landscape of biological research has undergone a profound transformation over the past decades, driven by the exponential growth of biological data and computational capabilities [[9](/article/10.1007/s44345-025-00037-5#ref-CR9 "Stein LD. Towards a cyberinfrastructure for the biological sciences: progress, visions and challenges. Nat Rev Genet. 2008;9(9):678–88.")]. Traditional approaches to understanding biological systems, once limited by experimental throughput and analytical capacity, have evolved into sophisticated computational frameworks capable of processing vast multi-dimensional datasets [[10](/article/10.1007/s44345-025-00037-5#ref-CR10 "Mukherjee A, Abraham S, Singh A, Balaji S, Mukunthan KS. From data to cure: a comprehensive exploration of multi-omics data analysis for targeted therapies. Mol Biotechnol. 2025;67(4):1269–89.")]. This evolution has been particularly pronounced in drug discovery, where the integration of computational methods has become essential for navigating the complexity of modern pharmaceutical research [[11](/article/10.1007/s44345-025-00037-5#ref-CR11 "Niazi SK, Mariam Z. Computer-aided drug design and drug discovery: a prospective analysis. Pharmaceuticals. 2023;17(1):22.")]. The emergence of high-throughput technologies, including next-generation sequencing, proteomics platforms, and metabolomics approaches, has generated unprecedented volumes of biological data [[12](/article/10.1007/s44345-025-00037-5#ref-CR12 "Vitorino R. Transforming clinical research: the power of high-throughput omics integration. Proteomes. 2024;12(3):25.")]. This data explosion, often characterized as biology’s transition to becoming the paradigmatic “big data” producer, has necessitated the development of advanced computational methodologies capable of extracting meaningful insights from these complex datasets [[13](/article/10.1007/s44345-025-00037-5#ref-CR13 "McCue ME, McCoy AM. The scope of big data in one medicine: unprecedented opportunities and challenges. Frontiers in veterinary science. 2017;4:194.")].

### 2.1 Integration of AI in bioinformatics

Artificial intelligence has arisen as a transformative force in bioinformatics, offering sophisticated approaches to data analysis, pattern recognition, and predictive modelling that were previously unattainable [[14](/article/10.1007/s44345-025-00037-5#ref-CR14 "Jamialahmadi H, Khalili-Tanha G, Nazari E, Rezaei-Tavirani M. Artificial intelligence and bioinformatics: a journey from traditional techniques to smart approaches. Gastroenterol Hepatol Bed Bench. 2024;17(3):241.")]. The integration of AI techniques, particularly machine learning and deep learning, has enabled researchers to move beyond descriptive analyses toward predictive modelling capabilities that can anticipate biological outcomes and guide experimental design [[15](/article/10.1007/s44345-025-00037-5#ref-CR15 "Pettit RW, Fullem R, Cheng C, Amos CI. Artificial intelligence, machine learning, and deep learning for clinical outcome prediction. Emerg Top Life Sci. 2021;5(6):729–45.")].

Machine learning applications in bioinformatics have demonstrated remarkable success across diverse domains, including gene identification, protein function prediction, and the discovery of functional modules within biological networks [[16](/article/10.1007/s44345-025-00037-5#ref-CR16 "Jin S, Zeng X, Xia F, Huang W, Liu X. Application of deep learning methods in biological networks. Brief Bioinform. 2021;22(2):1902–17.")]. Deep learning architectures, such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs), have proven particularly effective in handling the complex, hierarchical structures inherent in biological data [[17](/article/10.1007/s44345-025-00037-5#ref-CR17 "John C, Sahoo J, Madhavan M, Mathew OK. Convolutional neural networks: a promising deep learning architecture for biological sequence analysis. Curr Bioinform. 2023;18(7):537–58.")].

### 2.2 Significance in drug discovery

The pharmaceutical industry faces mounting pressure to increase efficiency and reduce the substantial costs and time requirements associated with bringing new therapies to market [[18](/article/10.1007/s44345-025-00037-5#ref-CR18 "Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today. 2012;17(19–20):1088–102.")]. Traditional drug discovery processes, characterized by high failure rates and extended development timelines, have created an urgent need for innovative approaches that can improve success rates while reducing resource requirements (Table [3](/article/10.1007/s44345-025-00037-5#Tab3)).

AI-driven methodologies have demonstrated significant potential in addressing these challenges through applications spanning the entire drug discovery pipeline [[19](/article/10.1007/s44345-025-00037-5#ref-CR19 "Ashiwaju BI, Orikpete OF, Uzougbo CG. The intersection of artificial intelligence and big data in drug disco

[... truncated ...]